342 related articles for article (PubMed ID: 31332522)
21. Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens.
Dai J; Zheng H; Jin J; Cheng Y; Xu H
Cancer Cytopathol; 2023 Jun; 131(6):365-372. PubMed ID: 36793190
[TBL] [Abstract][Full Text] [Related]
22. Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma.
Waters R; Sewastjanow-Silva M; Yamashita K; Abdelhakeem A; Iwata KK; Moran D; Elsouda D; Guerrero A; Pizzi M; Vicentini ER; Shanbhag N; Ta A; Chatterjee D; Ajani JA
JCO Precis Oncol; 2024 May; 8():e2300543. PubMed ID: 38781542
[TBL] [Abstract][Full Text] [Related]
23. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
Iwaya M; Hayashi H; Nakajima T; Matsuda K; Kinugawa Y; Tobe Y; Tateishi Y; Iwaya Y; Uehara T; Ota H
Histopathology; 2021 Aug; 79(2):227-237. PubMed ID: 33590909
[TBL] [Abstract][Full Text] [Related]
24. Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression.
Liu S; Zhang Z; Jiang L; Zhang M; Zhang C; Shen L
Cell Commun Signal; 2024 Jan; 22(1):27. PubMed ID: 38200591
[TBL] [Abstract][Full Text] [Related]
25. Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults.
Nakayama I; Shinozaki E; Sakata S; Yamamoto N; Fujisaki J; Muramatsu Y; Hirota T; Takeuchi K; Takahashi S; Yamaguchi K; Noda T
Cancer Sci; 2019 Apr; 110(4):1352-1363. PubMed ID: 30771244
[TBL] [Abstract][Full Text] [Related]
26. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers.
Zhong W; Lu Y; Ma Z; He Y; Ding Y; Yao G; Zhou Z; Dong J; Fang Y; Jiang W; Wang W; Huang Y
Front Immunol; 2022; 13():885424. PubMed ID: 35837391
[TBL] [Abstract][Full Text] [Related]
27. Jianpi Yangzheng decoction suppresses gastric cancer progression via modulating the miR-448/CLDN18.2 mediated YAP/TAZ signaling.
Xu X; Li Y; Zhang R; Chen X; Shen J; Yuan M; Chen Y; Chen M; Liu S; Wu J; Sun Q
J Ethnopharmacol; 2023 Jul; 311():116450. PubMed ID: 37023839
[TBL] [Abstract][Full Text] [Related]
28. Distinct expression pattern of claudin-6, a primitive phenotypic tight junction molecule, in germ cell tumours and visceral carcinomas.
Ushiku T; Shinozaki-Ushiku A; Maeda D; Morita S; Fukayama M
Histopathology; 2012 Dec; 61(6):1043-56. PubMed ID: 22803571
[TBL] [Abstract][Full Text] [Related]
29. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
[TBL] [Abstract][Full Text] [Related]
30. Claudins and Gastric Cancer: An Overview.
Hashimoto I; Oshima T
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053454
[TBL] [Abstract][Full Text] [Related]
31. Decreased expression of claudin-18.2 in alpha-fetoprotein-producing gastric cancer compared to conventional gastric cancer.
Weng W; Zhang M; Ni S; Tan C; Xu M; Wang X; Sun H; Wang L; Huang D; Sheng W
J Gastrointest Oncol; 2022 Jun; 13(3):1035-1045. PubMed ID: 35837176
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study.
Qi C; Chong X; Zhou T; Ma M; Gong J; Zhang M; Li J; Xiao J; Peng X; Liu Z; Li Z; Shen L; Zhang X
Chin J Cancer Res; 2024 Feb; 36(1):78-89. PubMed ID: 38455365
[TBL] [Abstract][Full Text] [Related]
33. Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: A retrospective analysis of 302 chinese patients.
Zhang Z; Liu X; Zhou L; Zhang M; Liang Z
Histol Histopathol; 2022 Oct; 37(10):1031-1040. PubMed ID: 35656795
[TBL] [Abstract][Full Text] [Related]
34. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
[TBL] [Abstract][Full Text] [Related]
35. Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer.
Matsusaka K; Ushiku T; Urabe M; Fukuyo M; Abe H; Ishikawa S; Seto Y; Aburatani H; Hamakubo T; Kaneda A; Fukayama M
Oncotarget; 2016 Sep; 7(39):64168-64181. PubMed ID: 27580354
[TBL] [Abstract][Full Text] [Related]
36. Recurrent Fusion Genes in Gastric Cancer: CLDN18-ARHGAP26 Induces Loss of Epithelial Integrity.
Yao F; Kausalya JP; Sia YY; Teo AS; Lee WH; Ong AG; Zhang Z; Tan JH; Li G; Bertrand D; Liu X; Poh HM; Guan P; Zhu F; Pathiraja TN; Ariyaratne PN; Rao J; Woo XY; Cai S; Mulawadi FH; Poh WT; Veeravalli L; Chan CS; Lim SS; Leong ST; Neo SC; Choi PS; Chew EG; Nagarajan N; Jacques PÉ; So JB; Ruan X; Yeoh KG; Tan P; Sung WK; Hunziker W; Ruan Y; Hillmer AM
Cell Rep; 2015 Jul; 12(2):272-85. PubMed ID: 26146084
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas.
Arnold A; Daum S; von Winterfeld M; Berg E; Hummel M; Rau B; Stein U; Treese C
Clin Transl Oncol; 2020 Dec; 22(12):2357-2363. PubMed ID: 32488802
[TBL] [Abstract][Full Text] [Related]
38. Profiling of gastric cancer cell-surface markers to achieve tumour-normal discrimination.
Toh J; Hoppe MM; Thakur T; Yang H; Tan KT; Pang B; Ho S; Roy R; Ho KY; Yeoh KG; Tan P; Sundar R; Jeyasekharan A
BMJ Open Gastroenterol; 2020 Aug; 7(1):. PubMed ID: 32816956
[TBL] [Abstract][Full Text] [Related]
39. Down-regulation of claudin-3 is associated with proliferative potential in early gastric cancers.
Okugawa T; Oshima T; Chen X; Hori K; Tomita T; Fukui H; Watari J; Matsumoto T; Miwa H
Dig Dis Sci; 2012 Jun; 57(6):1562-7. PubMed ID: 22290341
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of claudin-18 is associated with the proliferative and invasive potential of gastric cancer at the invasive front.
Oshima T; Shan J; Okugawa T; Chen X; Hori K; Tomita T; Fukui H; Watari J; Miwa H
PLoS One; 2013; 8(9):e74757. PubMed ID: 24073219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
